glp-1/gip agonist The activity of GLP-1 and GIP for Type 2 Diabetes and Obesity Triple GLP-1 / GIP /

Neuroinflammation, Alzheimers, and Cognition Neuroinflammation, Alzheimers, and Cognition Emerging research is also showing promise for GLP-1 drugs in treatment of neurodegenerative diseases

Cardiologists are invited to be more familiar with the members of this pharmacological family

10.1056/NEJMoa2028395 96 NietoL

Because compounded medications are not FDA-approved, transparency around pharmacy oversight, preparation standards, and testing can help consumers better understand how a medication is prepared and monitored

doi: 10.1097/HCO.0b013e3281532b53 79 SowersJR

2 Low risk of hypoglycemia GLP-1 agonists also have a low risk of hypoglycemia